Valuation: PFIZER

Market Cap 138B 138B 121B 112B 103B 194B 13,276B 198B 1,332B 522B 6,501B 519B 508B 22,383B P/E 2026 *
12.3x
P/E 2027 * 12.8x
Enterprise Value 188B 188B 164B 151B 140B 264B 18,011B 268B 1,806B 709B 8,819B 704B 689B 30,367B EV / Sales 2026 *
3.04x
EV / Sales 2027 * 3.06x
Free-Float
59.06%
Yield 2026 *
7.12%
Yield 2027 * 7.19%
Manager TitleAgeSince
Chief Executive Officer 64 01/01/2019
Director of Finance/CFO 60 02/05/2022
Chief Tech/Sci/R&D Officer - 01/01/2007
Director TitleAgeSince
Director/Board Member 68 01/09/2007
Director/Board Member 62 27/09/2013
Chairman 64 01/01/2020
Change 5-day change 1-year change 3-year change Capi.($)
-0.75%-5.57%+48.76%+156.76% 1,028B
-1.22%-4.59%+61.95%+57.98% 611B
+1.73%-2.10%+32.74%+83.51% 432B
+0.98%-1.40%+29.49%+23.12% 323B
-0.34%-3.10%+27.00%+43.66% 277B
+1.63%-11.76%+19.72%+23.20% 257B
+3.39%+2.29%-23.68%-38.33% 217B
+1.19%-2.37%+22.82%+57.69% 192B
+2.01%-2.52%+21.40%+70.88% 161B
Average +1.02%-5.24%+26.69%+53.16% 388.7B
Weighted average by Cap. +0.39%-5.52%+36.28%+77.87%

Financials

2026 *2027 *
Net sales 61.74B 61.74B 53.95B 49.88B 46.08B 86.78B 5,930B 88.35B 595B 233B 2,904B 232B 227B 9,999B 59.19B 59.19B 51.73B 47.82B 44.18B 83.2B 5,686B 84.71B 570B 224B 2,784B 222B 217B 9,587B
Net income 10.63B 10.63B 9.29B 8.59B 7.93B 14.94B 1,021B 15.21B 102B 40.17B 500B 39.92B 39.04B 1,721B 10.27B 10.27B 8.97B 8.29B 7.66B 14.43B 986B 14.69B 98.92B 38.81B 483B 38.57B 37.72B 1,663B
Net Debt 49.3B 49.3B 43.08B 39.83B 36.79B 69.29B 4,735B 70.54B 475B 186B 2,319B 185B 181B 7,984B 43.17B 43.17B 37.72B 34.87B 32.22B 60.67B 4,146B 61.77B 416B 163B 2,030B 162B 159B 6,991B
Logo PFIZER
Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows: - primary care products (47.4%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.; - specialty care products (26.2%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.; - oncology products (24.5%); - other (1.9%). The United States accounts for 60.8% of net sales.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
A